Antiangiogenics

No survival improvement from bevacizumab for patients with newly diagnosed glioblastoma

By

Adding bevacizumab (Avastin) to standard chemotherapy and radiation treatment does not improve survival for patients with newly diagnosed glioblastoma, an often deadly brain cancer, researchers reported.

Ramucirumab combination therapy failed to delay progression of advanced breast cancer

By

Adding the antibody therapy ramucirumab to docetaxel therapy did not delay disease progression for patients with HER2-negative, advanced breast cancer. These results, from a placebo-controlled, randomized, phase 3 clinical trial, were presented at the 2013 San Antonio Breast Cancer Symposium.

Imaging studies may predict tumor response to antiangiogenic drugs

By

Advanced imaging techniques may be able to distinguish which patients' tumors will respond to treatment with antiangiogenic drugs and which will not.

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs